What is the current valuation of the APAC Contract Research Organization Market?

The APAC Contract Research Organization Market was valued at 21.07 USD Billion in 2024. Read More

What is the projected market size for the APAC Contract Research Organization Market by 2035?

The market is projected to reach 40.01 USD Billion by 2035. Read More

What is the expected CAGR for the APAC Contract Research Organization Market during the forecast period?

The expected CAGR for the market from 2025 to 2035 is 6.0%. Read More

Which service type segment is anticipated to show the highest growth in the APAC market?

The Clinical Trials segment is expected to grow from 8.42 USD Billion to 15.5 USD Billion by 2035. Read More

How does the Oncology therapeutic area perform in the APAC Contract Research Organization Market?

The Oncology segment is projected to increase from 5.0 USD Billion to 10.0 USD Billion by 2035. Read More

What are the key end users in the APAC Contract Research Organization Market?

Pharmaceutical Companies, Biotechnology Companies, Medical Device Companies, and Academic Institutions are the primary end users. Read More

What is the projected growth for the Phase III study phase in the APAC market?

The Phase III study phase is expected to grow from 8.0 USD Billion to 15.0 USD Billion by 2035. Read More

Which companies are considered key players in the APAC Contract Research Organization Market?

Key players include IQVIA, PAREXEL International, Covance, and Charles River Laboratories. Read More

What is the anticipated growth for Laboratory Services in the APAC market?

Laboratory Services are projected to grow from 5.25 USD Billion to 10.0 USD Billion by 2035. Read More

How does the market for Preclinical Services compare to other service types?

Preclinical Services are expected to increase from 4.21 USD Billion to 8.0 USD Billion, indicating robust growth. Read More

Asia Pacific CRO Market

ID: MRFR/HC/11119-HCR

128 Pages

Vikita Thakur

Last Updated: April 06, 2026

Asia Pacific CRO Market Research Report Information By Type (Early Phase Development Services, Clinical Research Services, Laboratory Services, Post-Approval Services), By End User (Pharmaceutical and Biotechnology Companies and Medical Device Companies), and By Country (Japan, China, India, Australia And Rest of Asia) –Market Forecast Till 2035

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Service Type (USD Billion)
  1. 4.1.1 Clinical Trials
  2. 4.1.2 Preclinical Services
  3. 4.1.3 Laboratory Services
  4. 4.1.4 Consulting Services
2. 4.2 Healthcare, BY Therapeutic Area (USD Billion)
  1. 4.2.1 Oncology
  2. 4.2.2 Cardiology
  3. 4.2.3 Neurology
  4. 4.2.4 Infectious Diseases
  5. 4.2.5 Metabolic Disorders
3. 4.3 Healthcare, BY End User (USD Billion)
  1. 4.3.1 Pharmaceutical Companies
  2. 4.3.2 Biotechnology Companies
  3. 4.3.3 Medical Device Companies
  4. 4.3.4 Academic Institutions
4. 4.4 Healthcare, BY Study Phase (USD Billion)
  1. 4.4.1 Phase I
  2. 4.4.2 Phase II
  3. 4.4.3 Phase III
  4. 4.4.4 Phase IV
5. 4.5 Healthcare, BY Study Design (USD Billion)
  1. 4.5.1 Interventional Studies
  2. 4.5.2 Observational Studies
  3. 4.5.3 Registry Studies
  4. 4.5.4 Adaptive Trials
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 IQVIA (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 PAREXEL International (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Covance (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Charles River Laboratories (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Syneos Health (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Medpace (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Wuxi AppTec (CN)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 KCR (PL)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Novotech (AU)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
  10. 5.2.10 Clinipace (US)
    1. 5.2.10.1 Financial Overview
    2. 5.2.10.2 Products Offered
    3. 5.2.10.3 Key Developments
    4. 5.2.10.4 SWOT Analysis
    5. 5.2.10.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 APAC MARKET ANALYSIS BY SERVICE TYPE
3. 6.3 APAC MARKET ANALYSIS BY THERAPEUTIC AREA
4. 6.4 APAC MARKET ANALYSIS BY END USER
5. 6.5 APAC MARKET ANALYSIS BY STUDY PHASE
6. 6.6 APAC MARKET ANALYSIS BY STUDY DESIGN
7. 6.7 KEY BUYING CRITERIA OF HEALTHCARE
8. 6.8 RESEARCH PROCESS OF MRFR
9. 6.9 DRO ANALYSIS OF HEALTHCARE
10. 6.10 DRIVERS IMPACT ANALYSIS: HEALTHCARE
11. 6.11 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
12. 6.12 SUPPLY / VALUE CHAIN: HEALTHCARE
13. 6.13 HEALTHCARE, BY SERVICE TYPE, 2024 (% SHARE)
14. 6.14 HEALTHCARE, BY SERVICE TYPE, 2024 TO 2035 (USD Billion)
15. 6.15 HEALTHCARE, BY THERAPEUTIC AREA, 2024 (% SHARE)
16. 6.16 HEALTHCARE, BY THERAPEUTIC AREA, 2024 TO 2035 (USD Billion)
17. 6.17 HEALTHCARE, BY END USER, 2024 (% SHARE)
18. 6.18 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion)
19. 6.19 HEALTHCARE, BY STUDY PHASE, 2024 (% SHARE)
20. 6.20 HEALTHCARE, BY STUDY PHASE, 2024 TO 2035 (USD Billion)
21. 6.21 HEALTHCARE, BY STUDY DESIGN, 2024 (% SHARE)
22. 6.22 HEALTHCARE, BY STUDY DESIGN, 2024 TO 2035 (USD Billion)
23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY SERVICE TYPE, 2026-2035 (USD Billion)
  2. 7.2.2 BY THERAPEUTIC AREA, 2026-2035 (USD Billion)
  3. 7.2.3 BY END USER, 2026-2035 (USD Billion)
  4. 7.2.4 BY STUDY PHASE, 2026-2035 (USD Billion)
  5. 7.2.5 BY STUDY DESIGN, 2026-2035 (USD Billion)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

APAC Asia Pacific CRO Market Segmentation

Asia Pacific CRO Market By Service Type (USD Billion, 2026-2035)

Clinical Trials
Preclinical Services
Laboratory Services
Consulting Services

Asia Pacific CRO Market By Therapeutic Area (USD Billion, 2026-2035)

Oncology
Cardiology
Neurology
Infectious Diseases
Metabolic Disorders

Asia Pacific CRO Market By End User (USD Billion, 2026-2035)

Pharmaceutical Companies
Biotechnology Companies
Medical Device Companies
Academic Institutions

Asia Pacific CRO Market By Study Phase (USD Billion, 2026-2035)

Phase I
Phase II
Phase III
Phase IV

Asia Pacific CRO Market By Study Design (USD Billion, 2026-2035)

Interventional Studies
Observational Studies
Registry Studies
Adaptive Trials

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”